Antaros Medical proudly joins the BEAt-DKD consortium

After previously collaborating with the Innovative Medicines Initiative BEAt-DKD consortium, Antaros Medical now joins the project as an official member. The project is committed to deliver more effective tools for use in innovative clinical trials, with the aim to improve prevention and management of Diabetic Kidney Disease (DKD).

“We are proud to now be an official member of BEAt-DKD. This is an important platform to further explore imaging as a non-invasive tool to assess kidney health in clinical trials”

Lars Johansson, Chief Scientific Officer

About Diabetic Kidney Disease

Today, Chronic Kidney Disease (CKD) affects around 10% of the world’s population. DKD is the most common form of CKD. In its most advanced stage, DKD requires renal replacement therapy (dialysis or kidney transplant) imposing a high burden on both healthcare and the quality of life of patients. With the global increase of diabetes mellitus, the burden of DKD is expected to continue to grow.

Currently used biomarkers for DKD allows estimation of kidney function, but biopsy is necessary to understand disease aetiology. Recent advances in the CKD and DKD field have allowed that treatments for these patients are now on the way. However, there is a huge need to find new, non-invasive biomarkers to guide the further development of drugs in this area. MRI has great potential to non-invasively assess functional and morphologic, including fibrotic, changes in the kidney that may improve diagnosis, prognosis, and treatment monitoring in patients with DKD.

Share on Linkedin Share on Twitter